Systematic review of 12 studies (9 meta-analysed; n=3603) of adults with migraine on CGRP-targeted prevention: depression and anxiety scores fell at 3 months (e.g. HADS-D −1.35, BDI −3.70). The only placebo comparison (fremanezumab) was non-significant.
Meta-analysisn = 3,603
Al-Sayegh et al. Depressive and anxiety symptoms during CGRP-targeted migraine prevention: A systematic review and meta-analysis